Virtu KCG Holdings’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Virtu KCG Holdings’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-29,579	Closed	-$587K	–	3079
2017 Q1	$587K	Sell	29,579 -19,889	-40%	-$387K	0.02%	1208
2016 Q4	$907K	Buy	+49,468	New	+$929K	0.02%	857

Other funds holding FTXH

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RAM

Riggs Asset Management Dallas, Pennsylvania $486M AUM 59.08% 1-Year Est. Return

Virtu KCG Holdings's FTXH Position: Q2 2017 in Review

Virtu KCG Holdings sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q2 2017, closing a stake of 29,579 shares — an estimated $587K sold.

Virtu KCG Holdings first reported a position in FTXH in Q4 2016 and held it in 2 quarters. The position peaked at $907K in Q4 2016. 6 funds tracked by Wall St. Rank hold FTXH as of Q2 2017.

Virtu KCG Holdings reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q2 2017 after selling out during the quarter.
Virtu KCG Holdings sold 29,579 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2017, an estimated $587K.
Virtu KCG Holdings first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2016 and held it in 2 quarters.
Virtu KCG Holdings's First Trust Nasdaq Pharmaceuticals ETF position peaked at $907K in Q4 2016.
6 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.